



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/530,844	04/08/2005	Susanne Leonhartsberger	Leonhartsberger	3625

25889 7590 08/24/2006

WILLIAM COLLARD  
COLLARD & ROE, P.C.  
1077 NORTHERN BOULEVARD  
ROSLYN, NY 11576

EXAMINER
----------

RAGHU, GANAPATHIRAM

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 08/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 10/530,844	<b>Applicant(s)</b> LEONHARTSBERGER ET AL.	
	<b>Examiner</b> Ganapathirama Raghu	<b>Art Unit</b> 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_ MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 07 July 2006.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |  |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>05/09/05</u> . | 6) <input checked="" type="checkbox"/> Other: <u>SEQ ALIGN</u> .                       |

### **DETAILED ACTION**

Claims 1-9 are pending in this application are now under consideration for examination.

#### ***Election/Restrictions***

Applicant's election with traverse of Group II, claims 1-9 for prosecution in their response dated 07 July 2006 is acknowledged. The applicants' have requested reconsideration of restriction requirement (Groups II, III and IV) as the instant application claims a homoserine transsuccinylase with defined technical features, wherein the carboxy terminus of said enzyme is modified with insertions of defined polypeptides varying in sequence and length, i.e., to SEQ ID NO: 2 following the deletion of carboxy terminus (amino acid residues 297 onwards), the peptides with the SEQ ID NOs: 8 or 10 or 12 have been inserted and that any search of for the species of Group II would necessarily include a search of the species in Groups III and IV. The applicants' arguments are persuasive and therefore restriction is withdrawn and all species in groups II, III and IV are being examined.

#### ***Priority***

Acknowledgment is made of applicants' claim for foreign priority under 35 U.S.C. 119(a)-(d). This application is a 371 PCT/EP03/11486 filed on 10/16/2003 and claims the priority date of German application 102 49 642.0 filed on 10/24/2002. The examiner notes that no English translation has been filed for the German application and therefore for all examination purposes the 371 PCT/EP03/11486 filing date is considered as the priority date.

***Information Disclosure Statement***

The information disclosure statement (IDS) submitted on 09 May 2005 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

***Drawings***

Drawings are accepted for examination purposes only.

***Specification***

The disclosure is objected to because of the following informalities:

The specification contains drawing, however applicants have not provided any description for the figure. Correction is required.

***Claim Objections***

Claims 1, 3 and 9 are objected, due to the following informality: The following claims contain abbreviations; Claims 1, 3 and 9 have SAM in their claims. Examiner suggests at least in the first recitation of the abbreviations, expanding them to recite the full forms of what the abbreviation stands for. Appropriate correction is required.

***Claim Rejections: 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 and dependent claims 2-9 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 recites "...this change..". Claim previously stated that "at least 2 amino acid changes" in line 9. Is "this change" in both the amino acids or change is in only one amino acid? Clarification and correction is required.

Claim 8 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 recites the phrase "...preferably". Does the claim only includes a specific strain of *E.coli* only or other gram-negative including *E.coli* strains. Clarification is required.

***Claim Rejections 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 1 and claims 2-3 and 5-9 depending therefrom are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1-3 and 5-9, are directed to a mutant homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM as compared to the wild-type enzyme comprising the

Art Unit: 1652

constituent sequence of TyrGlnXaaThrPro with the Thr being between position 285 and 310 and said mutant exhibits a change of at least two amino acids as compared to the wild-type enzyme, said change being in the Thr or C-terminally thereof, a metA allele encoding homoserine transsuccinylase, vector comprising said mutant, transformed host cell and the method of preparing L-methionine or SAM. Claims 1-3 and 5-9 are rejected under this section 35 U.S.C. 112, because the claims are directed to any or all homoserine transsuccinylase comprising the constituent sequence of TyrGlnXaaThrPro at position 285-310, involves a genus of polypeptides including variants, mutants and recombinants from any source with no support in the specification for the structural details associated with the function i.e., homoserine transsuccinylase activity with reduced sensitivity to L-methionine or SAM. No description of identifying characteristics of all of the polypeptides of an isolated homoserine transsuccinylase, including variants, mutants and recombinants from any source has been provided by the applicants in the specification. No information, beyond the characterization of the polypeptide, homoserine transsuccinylase from *E.coli* wild-type enzyme of SEQ ID NO: 2 and three mutants, wherein the amino acid residues 297 onwards of said wild-type enzyme sequence has been replaced with SEQ ID NO: 8 or 10 or 12 said mutants with reduced sensitivity to L-methionine or SAM has been provided by the applicants, which would indicate that they had possession of the claimed genus of all of the polypeptides of an isolated homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM, including variants, mutants and recombinants from any source. Therefore, one skilled in the art cannot reasonably conclude that applicant had possession of the claimed invention at the time the instant application was filed. Applicant is referred to the revised guidelines concerning compliance with the written description

Art Unit: 1652

requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at [www.uspto.gov](http://www.uspto.gov).

Claims 1-3 and 5-9 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated homoserine transsuccinylase, said wild-type enzyme isolated from *E.coli* and comprising the sequence of SEQ ID NO: 2 and three mutants derived by deleting the amino acid residues 297 onwards in said wild-type enzyme carboxy terminus and replaced with the polypeptide sequence of SEQ ID NO: 8 or 10 or 12 and said mutants exhibit reduced sensitivity to L-methionine or SAM, vector comprising polynucleotides encoding said polypeptides, host cell and method of preparing L-methionine or SAM, does not reasonably provide enablement for any or all homoserine transsuccinylase comprising the constituent sequence of TyrGlnXaaThrPro at position 285-310, including variants, mutants and recombinants with reduced sensitivity to L-methionine or SAM from any source, vector comprising polynucleotides encoding said polypeptides, host cell and method of preparing L-methionine or SAM. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and or use the invention commensurate in scope with the claim.

Factors to be considered in determining whether undue experimentation is required are summarized in *In re Wands* (858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988)) as follows: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the

Art Unit: 1652

prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claim(s).

Claims 1-3 and 5-9 are so broad as to encompass any or all homoserine transsuccinylase comprising the constituent sequence of TyrGlnXaaThrPro at position 285-310, including variants, mutants and recombinants from any source with reduced sensitivity to L-methionine or SAM, vector comprising polynucleotides encoding said polypeptides, host cell and method of preparing L-methionine or SAM. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of polypeptides with homoserine transsuccinylase activity broadly encompassed by the claims. Since the amino acid sequence of a protein encoded by a polynucleotide determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and obtain the desired activity requires knowledge and guidance with regard to which amino acids in the protein's sequence and the respective codons in its polynucleotide, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the encoded proteins' structure relates to its function. However, in this case the disclosure is limited to an isolated homoserine transsuccinylase, said wild-type enzyme isolated from *E.coli* and comprising the sequence of SEQ ID NO: 2 and three mutants derived by deleting the amino acid residues 297 onwards in said wild-type enzyme carboxy terminus and replaced with the polypeptide sequence of SEQ ID NO: 8 or 10 or 12 and said mutants exhibit reduced sensitivity to L-methionine or SAM, vector comprising polynucleotides encoding said polypeptides, host cell and method of preparing L-methionine or SAM. In view of the great breadth of the claims, amount of experimentation



required to make the claimed polypeptides the lack of guidance, working examples, and unpredictability of the art in predicting function from a polypeptide primary structure (e.g., see Ngo et al. in *The Protein Folding Problem and Tertiary Structure Prediction*, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495), the claimed invention would require undue experimentation. As such, the specification fails to teach one of ordinary skill how to use the full scope of the polypeptides encompassed by this claim.

While enzyme isolation techniques, recombinant and mutagenesis techniques are known, and it is not routine in the art to screen for multiple substitutions or multiple modifications as encompassed by the instant claims, the specific amino acid positions within a protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining the desired activity/utility are limited in any protein and the result of such modifications is unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g. multiple substitutions or deletions.

The specification does not support the broad scope of the claims for any or all homoserine transsuccinylase comprising the constituent sequence of TyrGlnXaaThrPro at position 285-310, including variants, mutants and recombinants from any source with reduced sensitivity to L-methionine or SAM, vector comprising polynucleotides encoding said polypeptides, host cell and method of preparing L-methionine or SAM, because the specification does not establish: (A) regions of the protein/polynucleotide structure which may be modified to produce the desired effect on the encoded homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM wherein the polypeptides are from any source; (B) the general tolerance

Art Unit: 1652

of the polypeptide and the polynucleotide encoding homoserine transsuccinylase activity to modification and extent of such tolerance; (C) a rational and predictable scheme for modifying any amino acid residue or the respective codon in the polynucleotide with an expectation of obtaining the desired biological function, i. e., homoserine transsuccinylase mutants exhibiting reduced sensitivity to L-methionine or SAM; and (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims which broadly encompass any or all homoserine transsuccinylase comprising the constituent sequence of TyrGlnXaaThrPro at position 285-310, including variants, mutants and recombinants from any source with reduced sensitivity to L-methionine or SAM, vector comprising polynucleotides encoding said polypeptides, host cell and method of preparing L-methionine or SAM. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of polynucleotides and encoding polypeptides of homoserine transsuccinylase activity having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir, 1988).

### ***Claim Rejections 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1652

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3 and 5-9 are rejected under 35 U.S.C. 102(b) as being anticipated by patent assigned to AJINOMOTO (JP 2000139471 A, published 05/23/2000) when given the broadest interpretation. Claims 1-3 and 5-9 are directed to a mutant homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM as compared to the wild-type enzyme comprising the constituent sequence of TyrGlnXaaThrPro with the Thr being between position 285 and 310 and said mutant exhibits a change of at least two amino acids as compared to the wild-type enzyme, said change being in the Thr or C-terminally thereof, a metA allele encoding homoserine transsuccinylase, vector comprising said mutant, transformed host cell and the method of preparing L-methionine or SAM. Patent assigned to AJINOMOTO (JP 2000139471 A, published 05/23/2000) disclose preparing L-methionine with a modified Met producing microorganism (*E.coli*) deleted for a repressor of the Met biosynthetic system, capable of producing Met, particularly with enhanced homoserine transsuccinylase activity and released of concerted inhibition with Met and SAM and a DNA encoding a homoserine transsuccinylase having a variation at Ile296 to Ser and Pro298 to Leu of SEQ ID NO: 2 (change in constituent sequence of TyrGlnXaaThrPro or in Thr or C-terminally thereof of wild-type metA allele encoding homoserine transsuccinylase). Therefore the reference of AJINOMOTO (JP 2000139471 A, published 05/23/2000, claiming the priority of 1998JP-0326717 filed on 11/17/1988) anticipates the claims 1, 3 and 5-9 as written.

Claims 1-3 are rejected under 35 U.S.C. 102(b) as being anticipated by Nelson et al., (Nature 1999, Vol. 399: 323-329) when given the broadest interpretation. Claims 1-3 are directed to a mutant homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM as compared to the wild-type enzyme comprising the constituent sequence of TyrGlnXaaThrPro with the Thr being between position 285 and 310 and said mutant exhibits a change of at least two amino acids as compared to the wild-type enzyme, said change being in the Thr or C-terminally thereof, furthermore said change is of at least 5-10 amino acids. Nelson et al., (*supra*) disclose a homoserine transsuccinylase from *Thermotoga maritima* having a C-terminal variation from amino acid residues 296 onwards, having carboxy terminus of YQKTPY (amino acid residues 293-298; see sequence alignment provided), the sequence disclosed by Nelson et al., lacks the amino acid residues at the carboxy terminus spanning from 299-309 of the wild-type sequence of SEQ ID NO: 2 of the instant application. Said reference is silent regarding the sensitivity to L-methionine or SAM, however examiner takes the position that said homoserine transsuccinylase has a variation in the carboxy terminus other than the constituent sequence of TyrGlnXaaThrPro and therefore the polypeptide disclosed by Nelson et al., should also possess similar biochemical properties. Therefore the reference of Nelson et al., (*supra*) anticipates the claims 1-3 as written.

Claims 1-3 are rejected under 35 U.S.C. 102(b) as being anticipated by Goodner et al., (Science 2001, Vol. 294: 2323-2328) when given the broadest interpretation. Claims 1-3 are directed to a mutant homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM as compared to the wild-type enzyme comprising the constituent sequence of

TyrGlnXaaThrPro with the Thr being between position 285 and 310 and said mutant exhibits a change of at least two amino acids as compared to the wild-type enzyme, said change being in the Thr or C-terminally thereof, furthermore said change is of at least 5-10 amino acids. Goodner et al., (*supra*) disclose a homoserine transsuccinylase from *Agrobacterium tumefaciens* having a C-terminal variation from amino acid residues 296 onwards, having a carboxy terminus of WRSHAHLLFFGNWINEIQY (amino acid residues 285-302; see sequence alignment provided), the sequence disclosed by Goodner et al., lacks the amino acid residues at the carboxy terminus spanning from 299-309 of the wild-type sequence of SEQ ID NO: 2 of the instant application. Said reference is silent regarding the sensitivity to L-methionine or SAM, however examiner takes the position that said homoserine transsuccinylase has a variation in the carboxy terminus other than the constituent sequence of TyrGlnXaaThrPro and therefore the polypeptide disclosed by Goodner et al., should also possess similar biochemical properties. Therefore the reference of Goodner et al., (*supra*) anticipates the claims 1-3 as written.

Claims 1-3 are rejected under 35 U.S.C. 102(b) as being anticipated by DelVecchio et al., (PNAS 2002, Vol. 99 (1): 443-448) when given the broadest interpretation. Claims 1-3 are directed to a mutant homoserine transsuccinylase with reduced sensitivity to L-methionine or SAM as compared to the wild-type enzyme comprising the constituent sequence of TyrGlnXaaThrPro with the Thr being between position 285 and 310 and said mutant exhibits a change of at least two amino acids as compared to the wild-type enzyme, said change being in the Thr or C-terminally thereof, furthermore said change is of at least 5-10 amino acids. DelVecchio et al., (*supra*) disclose a homoserine transsuccinylase from *Brucella melitensis*

Art Unit: 1652

having a C-terminal variation from amino acid residues 296 onwards, having a carboxy terminus of SHAHLFFGNWINEMYQST (amino acid residues 285-312; see sequence alignment provided), the sequence disclosed by DelVecchio et al., lacks the amino acid residues at the carboxy terminus spanning from 299-309 of the wild-type sequence of SEQ ID NO: 2 of the instant application. Said reference is silent regarding the sensitivity to L-methionine or SAM, however examiner takes the position that said homoserine transsuccinylase has a variation in the carboxy terminus other than the constituent sequence of TyrGlnXaaThrPro and therefore the polypeptide disclosed by DelVecchio et al., should also possess similar biochemical properties. Therefore the reference of DelVecchio et al., (*supra*) anticipates the claims 1-3 as written.


### Conclusion

None of the claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathirama Raghu whose telephone number is 571-272-4533. The examiner can normally be reached on 8 am - 5 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300 for regular communications and for After Final communications. Any inquiry of a general nature or relating to the status of the application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ganapathirama Raghu, Ph.D.  
Patent Examiner  
Art Unit 1652  
Aug. 06, 2006.

  
REBECCA E. PRIDDY  
PRIMARY EXAMINER  
GROUP 1800  
1600

QY 181 RGFDDSLAPHSRYADFPALIRDTDLLEILAEETEGDAYLFASKDKRIAFVTGHPYDA 240  
 DB 181 NGFSDDFQVPVSRWTEVRADIEKHPELEILMESDEMGVCLAEKAGNRLNFMNHYEYDS 240  
 QY 241 QTLAQEFPRDVEAGLDPDPVNYFPHNDPONTPRASWRSHGNLLFTWNLNYYVYQ 295  
 DB 241 TSLADEYFRDYNVSGVPIKPLPHDYFPHNDPELAPLNRWRSHAHLLFFGNWIN-EIYQ 294

RESULT 14  
 C97685  
 homoserine O-succinyltransferase (homoserine o-transsuccinylase) (hts) [imported] - Agrobacterium tumefaciens  
 C;Species: Agrobacterium tumefaciens  
 C;Date: 30-Sep-2001 #sequence\_revision 30-Sep-2001 #text\_change 07-Jul-2003  
 C;Accession: C97685  
 R;Goodner, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Qurollo, B.; Goldman, A.; Liu, F.; Wollam, C.; Allinger, M.; Doughty, D.; Scott, C.; Lappas, C.; Markelz, B.; Science 294, 2323-2328, 2001  
 A;Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tumefaciens  
 A;Reference number: A97359; MUID:21608551; PMID:11743194  
 A;Accession: C97685  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-316 <KUR>  
 A;Cross-references: UNIPARC:UPI00000D1FCF; GB:AE007869; PIDN:AAK8436.1; PID:g15157931;  
 C;Genetics:  
 A;Gene: AGR C.4927  
 A;Map position: circular chromosome  
 C;Superfamily: homoserine O-succinyltransferase

Query Match 40.1%; Score 710.9; DB 2; Length 316;  
 Best Local Similarity 45.4%; Pred. No. 9.4e-23;  
 Matches 134; Conservative 57; Mismatches 103; Indels 1; Gaps 1;

QY 1 MPTRVPDELPAVNFLEENVFVMTTSRASQEIIRPLKVLINLMPKIKIETENQFLRLSN 60  
 DB 9 MPKIPDTLPAFETLVHEGVVMTETAIRQDIRPLQIGLLNLMFNKIKTEIQWALVGA 68  
 QY 61 SPLQVDIQLLRIDRSRNPFAHLNPNFYCNFEDIQONFDGLIVTGAPLGLVFNVDVAY 120  
 DB 69 SPLQVELSLIRIGGHRANKTPPEHLLSFYQWTEVVRHKKFDGFIITGAPIELLDYEDVTY 128  
 QY 121 WPOIKQVLEWSKDHVTSTLFCWAVQAALNLYGIPKOTRTEKLSGVVHHILPHALLT 180  
 DB 129 WNEMQQIFETQTNVHSLNVCWGAAMAIYHFHGVPKYELKEKAFGVYRHNLSFSSIYL 188  
 QY 181 RGFDDSLAPHSRYADFPALIRDTDLLEILAEETEGDAYLFASKDKRIAFVTGHPYDA 240  
 DB 189 NGFSDDFQVPVSRWTEVRADIEKHPELEILMESDEMGVCLAEKAGNRLNFMNHYEYDS 248  
 QY 241 QTLAQEFPRDVEAGLDPDPVNYFPHNDPONTPRASWRSHGNLLFTWNLNYYVYQ 295  
 DB 249 TSLADEYFRDYNVSGVPIKPLPHDYFPHNDPELAPLNRWRSHAHLLFFGNWIN-EIYQ 302

RESULT 15  
 AD3607  
 homoserine O-succinyltransferase (EC 2.3.1.46) [imported] - Brucella melitensis (strain C;Species: Brucella melitensis  
 C;Date: 01-Feb-2002 #sequence\_revision 01-Feb-2002 #text\_change 07-Jul-2003  
 C;Accession: AD3607  
 R;Belvecchio, V.G.; Kapatal, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Los, T.; Ivanova, M.; Mazur, M.; Goltzman, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letessier, P.; Natl. Acad. Sci. U.S.A. 99, 443-448, 2002  
 A;Title: The genome sequence of the facultative intracellular pathogen Brucella melitensis  
 A;Reference number: AD3252; PMID:11756688  
 A;Accession: AD3607  
 A;Status: preliminary  
 A;Molecule type: DNA  
 A;Residues: 1-322 <KUR>  
 A;Cross-references: UNIPARC:UPI00000585FA; GB:AE008918; PIDN:AAL54023.1; PID:g17984975;  
 A;Experimental source: strain 16M  
 C;Genetics:

A;Gene: BMEL10781

A;Map position: II

C;Superfamily: homoserine O-succinyltransferase

C;Keywords: acyltransferase; coenzyme A

Query Match 36.5%; Score 647.1; DB 2; Length 322;

Best Local Similarity 38.8%; Pred. No. 5.6e-20;

Matches 124; Conservative 61; Mismatches 106; Indels 29; Gaps 3;

QY 1 MPTRVPDELPAVNFLEENVFVMTTSRASQEIIRPLKVLINLMPKIKIETENQFLRLSN 60

DB 17 MPKIPDDLPATSVLEAEGVVWVREADAVRQDIRPLRIGLLNLMFNKVTTETQIARLIGA 76

QY 61 SPLQVDIQLLRIDRSRNPFAHLNPNFYCNFEDIQONFDGLIVTGAPLGLVFNVDVAY 120

DB 77 TPLQVELTLVRMTNHNVARHTPADHMLSFYCPWEENVDRQDFGVITGAPVERLPFEVTV 136

QY 121 WPOIKQVLEWSKDHVTSTLFCWAVQAALNLYGIPKOTRTEKLSGVVHHILPHALLT 180

DB 137 WDEMRRVFDVTQSHVHRTLNICWAAQAAVYHFHGMKKYDLPKASGVFRQSRSLVASPYL 196

QY 181 RGFDDSLAPHSRY-----ADFPALIRDTDLLEILAEETEGDAYLFASKDKRIAFVTGH 235

DB 197 RGFSDDFPAIPVSRWTEVRKSDIPAD-----SGLKVLVDSTETGLCLDDDPHRSLSHMFNH 251

QY 236 PEYDAQTLAQEFPRDVEAGLDPDPVNYFPHNDPONTPRASWRSHGNLLFTWNLNYYVYQ 295

DB 252 VEYDTTSLADEYFRDIQVQPEAKVPVNYFPDQAKRPPENRWRSHAHLLFGNWIN----- 306

QY 296 ISYIHVYLLVNNSTELWMHT 315

DB 307 -----EMYQST 312

Search completed: August 1, 2006, 04:30:16

Job time : 22.8385 secs

Db 124 WNELKQINENKTNVTSILHCWGAQAGLFYHGVKPLPKQGVPHKINPNVKKL 180  
Qy 181 RGFDDSLAPHSRYADFPALIRDTLEILAEETEGDAYLPASKDKRIAFVTHPEYDA 240  
Db 181 RGFDDSLAPHSRYADFPALIRDTLEILAEETEGDAYLPASKDKRIAFVTHPEYDA 240  
Qy 241 QTLAQEFPRDVEAGLDPDPVNYPPHNDPONTPRASRSHGNTLFTWNLNYYVYQ 295  
Db 241 CTLOQYERDRARGNIOVPEYFPNDATRKPLLRWRAHSYLLFSNWLNYVYQ 295

RESULT 8  
C72324  
homoserine O-succinyltransferase - Thermotoga maritima (strain MSB8)  
C:Species: Thermotoga maritima  
C>Date: 11-Jun-1999 #sequence\_revision 11-Jun-1999 #text\_change 09-Jul-2004  
C:Accession: C72324  
R:Nelson, K.E.; Clayton, R.A.; Gill, S.R.; Gwinn, M.L.; Dodson, R.J.; Haft, D.H.; Hickey, G.; Garret, M.M.; Stewart, A.M.; Cotton, M.D.; Pratt, M.S.; Phillips, C.A.; Richardson, D.; C.M.  
Nature 399, 323-329, 1999  
A>Title: Evidence for lateral gene transfer between Archaea and Bacteria from genome seq  
A:Reference number: A72200; MUID:99287316; PMID:10360571  
A:Accession: C72324  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-304 <R>  
A:Cross-references: UNIPROT:Q9WY23; UNIPARC:UPI000012EP5A; GB:AE001753; GB:AE000512; NID  
A:Experimental source: strain MSB8  
C:Genetics:  
A:Gene: TM0881  
C:Superfamily: homoserine O-succinyltransferase

Query Match 46.3%; Score 821.6; DB 2; Length 304;  
Best Local Similarity 47.5%; Pred. No. 1.4e-27;  
Matches 153; Conservative 54; Mismatches 91; Indels 24; Gaps 2;

Qy 1 MPRIVPDELPAVNFLENVFMVMTTSRASGEIRPLKVLILNLMPPKTIETENQFLRLSN 60  
Db 1 MPINVPGLPAVKVLAKGEIFVMTSEKRAIHQDIRPLEILILNLMPPDKIKTEIQLRLGN 60  
Qy 61 SPLQVDIQLLRIDRESRNTPAEHLNPNFYCNFEDIQDNFGLIVTGAPGLVEFNDVAY 120  
Db 61 TPLQVNTLLTETHKPHHTPIELHKKFTTSVAVKORRFGDITGAPVELLPFEVDY 120  
Qy 121 WPOIKQVLESKDHVTSTLFCWAVQAALNLYGIPKQTRTEKLSGVYEHHLPHALLT 180  
Db 121 WEELTEIMENSRHNVYSTMFICWAAQAGLYFYGIPKVELPQKLSGVYKHVA-KDSVLF 179  
Qy 181 RGFDDSLAPHSRYADFPALIRDTLEILAEETEGDAYLPASKDKRIAFVTHPEYDA 240  
Db 180 RGHDDFWAPHSRYTEVKEDIDKVPLEILAESEAGVYVANKSERQIFVTGHPYDR 239  
Qy 241 QTLAQEFPRDVEAGLDPDPVNYPPHNDPONTPRASRSHGNTLFTWNLNYYVYQISVIH 300  
Db 240 YTLRDEYRDDGRMLKVPINIPANYPFNDDFTKPIILTWSHAHLFSNWLNYCIYQ----- 294  
Qy 301 HYLLVNNSTELMWHTRLIKRPH 322  
Db 295 -----KTPY 298

RESULT 9  
C72125  
homoserine trans-succinylase [imported] - Clostridium acetobutylicum  
C:Species: Clostridium acetobutylicum  
C>Date: 14-Sep-2001 #sequence\_revision 14-Sep-2001 #text\_change 09-Jul-2004  
C:Accession: C97125  
R:Noelling, J.; Breston, G.; Omelchenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee, J.; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.  
J. Bacteriol. 183, 4833-4838, 2001  
A>Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Cld

Db 124 WNELKQINENKTNVTSILHCWGAQAGLFYHGVKPLPKQGVPHKINPNVKKL 180  
Qy 181 RGFDDSLAPHSRYADFPALIRDTLEILAEETEGDAYLPASKDKRIAFVTHPEYDA 240  
Db 181 RGFDDSLAPHSRYADFPALIRDTLEILAEETEGDAYLPASKDKRIAFVTHPEYDA 240  
Qy 241 QTLAQEFPRDVEAGLDPDPVNYPPHNDPONTPRASRSHGNTLFTWNLNYYVYQ 295  
Db 241 CTLOQYERDRARGNIOVPEYFPNDATRKPLLRWRAHSYLLFSNWLNYVYQ 295

Query Match 44.5%; Score 790; DB 2; Length 301;  
Best Local Similarity 45.8%; Pred. No. 3.2e-26;  
Matches 147; Conservative 49; Mismatches 99; Indels 0; Gaps 0;

Qy 1 MPRIVPDELPAVNFLENVFMVMTTSRASGEIRPLKVLILNLMPPKTIETENQFLRLSN 60  
Db 1 MPRIKIDKPAVELLRTEINIFVMDQRAHQDIRPLKILILNLMPPKMTQTLRLAN 60  
Qy 61 SPLQVDIQLLRIDRESRNTPAEHLNPNFYCNFEDIQDNFGLIVTGAPGLVEFNDVAY 120  
Db 61 SPLQVNTFTHTQTHKSQNTSKEHLIKFYETFEIKNNKFDGMIVTGAPVETLSPENVY 120  
Qy 121 WPOIKQVLESKDHVTSTLFCWAVQAALNLYGIPKQTRTEKLSGVYEHHLPHALLT 180  
Db 121 WEELCRIFDMSVNVVTSTIHCWGAQAGLYHYGIPKVELHEKLFVGFKNLTERNIKLT 180  
Qy 181 RGFDDSLAPHSRYADFPALIRDTLEILAEETEGDAYLPASKDKRIAFVTHPEYDA 240  
Db 181 RGFDDFWAPHSRYTYVREDIKKPSKILAESEAGAYIVASENGKNIFVWGHAETDG 240  
Qy 241 QTLAQEFPRDVEAGLDPDPVNYPPHNDPONTPRASRSHGNTLFTWNLNYYVYQ 295  
Db 241 DTLNLEYIRDKNQGNIKIPANYPKNDPEKGPMTWRGHANLLFSNWLNYVYQ 295

RESULT 10  
A98051  
homoserine O-succinyltransferase [SC 2.3.1.46] [imported] - Streptococcus pneumoniae  
C:Species: Streptococcus pneumoniae  
C>Date: 22-Oct-2001 #sequence\_revision 22-Oct-2001 #text\_change 07-Jul-2003  
C:Accession: A98051  
R:Hoskins, J.A.; Alborn Jr., W.; Arnold, J.; Blaszcak, L.; Burgett, S.; DeHoff, B.S.; e, R.; LeBlanc, D.J.; Lee, L.N.; Lefkowitz, B.J.; Lu, J.; Matsushima, P.; McAhren, S.; J. P.; Sun, P.M.; Winkler, M.E.  
J. Bacteriol. 183, 5709-5717, 2001  
A:Authors: Yang, Y.; Young-Bellido, M.; Zhao, G.; Zook, C.; Baltz, R.H.; Jaskunas, S.R.  
A>Title: Genome of the Bacterium Streptococcus pneumoniae Strain R6.  
A:Reference number: A97872; MUID:21429245; PMID:11544234  
A:Accession: A98051  
A>Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-314 <R>  
A:Cross-references: UNIPARC:UPI000008365A; GB:AE007317; PIDN:AAL00238.1; PID:gl5459089;  
A:Gene: meta  
C:Superfamily: homoserine O-succinyltransferase  
C:Keywords: acyltransferase; coenzyme A

Query Match 43.5%; Score 772; DB 2; Length 314;  
Best Local Similarity 48.8%; Pred. No. 2.2e-25;  
Matches 144; Conservative 53; Mismatches 98; Indels 0; Gaps 0;

Qy 1 MPRIVPDELPAVNFLENVFMVMTTSRASGEIRPLKVLILNLMPPKTIETENQFLRLSN 60  
Db 1 MPRIKIDKPAVELLRTEINIFVMDQRAHQDIRPLKILILNLMPPKMTQTLRLAN 60  
Qy 61 SPLQVDIQLLRIDRESRNTPAEHLNPNFYCNFEDIQDNFGLIVTGAPGLVEFNDVAY 120  
Db 61 TPLQVDIQLLRIDRESRNTPAEHLNPNFYCNFEDIQDNFGLIVTGAPGLVEFNDVAY 120  
Qy 121 WPOIKQVLESKDHVTSTLFCWAVQAALNLYGIPKQTRTEKLSGVYEHHLPHALLT 180



	Qy	181	RGFDDSLAPHSRYADPAALIRDYTDLEILAEETEGDAYLFASKKRIAFVGTGHPDYDA	240
	Dd	181	NGFSDDPQVPVSRTWERRADIKEKHPEILEIMESDEMGVCILAHEKAGNRLYMNFHYEYS	240
	Qy	241	QTLAQEFROVEAGDSDGVPNYPFHNDPQNTPPASWRSHGNLLFTNLWNYYVQ	295
	Dd	241	TSLADEYFRDVNSGVPIKLPHDYFPHNDPELAPLNWRSHAHLFFGGWIN-EIVQ	294

RESULT 14

C97685

homoserine O-succinyltransferase (homoserine o-transsuccinylase) (hts) [imported] - Agro

C;Species: Agrobacterium tumefaciens

C;Date: 30-Sep-2001 #sequence\_revision 30-Sep-2001 #text\_change 07-Jul-2003

C;Accession: C97685

R;Goodner, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Quorllo, B.; Goldman,  
A.; Liu, F.; Wollam, C.; Allinger, M.; Doughty, D.; Scott, C.; Lappas, C.; Markelz, B.;  
Science 294, 2323-2328, 2001

A;Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tum  
A;Reference number: A97359; MUID:21608551; PMID:11743194

A;Accession: C97685

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-316 <CUR>

A;Cross-references: UNIPARC:UPI00000D1FCF; GB:AE007869; PIDN:AAK88436.1; PID:g15157931;  
C;Genetics:

A;Gene: AGR\_C\_4927

A;Map position: circular chromosome

C;Superfamily: homoserine O-succinyltransferase

Query Match	40.1%	Score	710.9	DB 2	Length	316	
Best Local Similarity	45.4%	Pred. NO.	9.4e-23				
Matches 134; Conservative		57; Mismatches	103	Indels	1	Gaps	1

Qy	1	MP1RV	DELPA	VN	FL	RE	NU	V	M	T	T	S	R	A	G	O	E	I	R	P	L	K	V	L	I	N	L	M	P	K	I	E	T	N	O	F	L	L	S	N	60													
Db	9	MP1KI	P	T	L	P	A	F	E	T	L	V	H	E	G	V	R	M	T	A	I	R	O	I	P	L	O	I	G	L	N	L	M	P	N	K	I	K	T	E	I	O	A	R	L	V	G	68						
Qy	61	SP1QV	I	D	L	R	I	D	S	R	E	S	R	N	T	P	A	E	H	N	F	N	F	C	N	F	E	D	I	O	N	F	D	L	I	T	G	A	P	L	G	L	V	E	N	D	V	120						
Db	69	SP1QV	E	L	S	L	R	I	C	G	H	R	A	K	N	T	P	E	E	H	L	S	F	Y	Q	T	W	E	E	R	K	P	D	C	F	I	T	G	A	P	I	L	L	E	D	E	V	T	128					
Qy	121	W	P	O	I	K	O	V	L	E	S	K	D	H	V	T	S	T	L	F	C	W	A	O	A	N	L	I	Y	G	I	P	K	O	T	R	T	E	K	S	G	V	Y	E	H	I	L	P	H	A	L	L	T	180
Db	129	W	N	E	M	O	O	I	F	E	T	O	N	V	H	S	T	L	V	C	G	A	M	A	I	V	H	F	G	V	P	K	Y	E	L	K	E	K	A	F	G	V	Y	R	H	N	L	S	P	S	T	Y	L	188
Qy	181	R	G	P	D	S	F	L	A	P	H	S	R	Y	A	D	P	P	A	L	I	R	D	T	O	E	I	L	A	E	T	E	G	D	A	V	L	F	A	S	K	O	K	R	I	A	V	T	C	H	P	E	D	240
Db	189	N	G	S	D	D	F	O	P	V	S	R	W	T	E	V	R	R	A	D	I	E	K	H	P	E	L	I	M	E	S	D	E	N	G	V	C	L	A	E	K	A	G	N	L	M	F	N	H	V	E	D	248	
Qy	241	Q	T	L	A	Q	E	F	F	R	D	V	E	A	G	L	D	P	D	V	P	N	T	P	P	H	N	D	P	O	N	T	P	R	A	S	W	R	S	H	G	N	L	F	T	N	L	N	Y	Y	Q	295		
Db	249	T	S	L	A	S	D	F	R	D	V	N	S	G	V	I	K	L	P	H	D	T	F	P	H	N	D	P	E	L	A	P	L	N	R	W	S	H	A	H	I	F	F	G	N	W	I	N	-E	I	Y	O	302	

RESULT 15  
AD3607  
homoserine o-succinyltransferase (EC 2.3.1.46) [imported] - *Bruceella melitensis* (strain  
C:Species: *Bruceella melitensis*  
C:Date: 01-Feb-2002 #sequence\_revision 01-Feb-2002 #text\_change 07-Jul-2003  
C:Accession: AD3607  
R:DelVecchio, V.G.; Kapatal, V.; Redkar, R.J.; Patra, G.; Muier, C.; Los, T.; Ivanova,  
M.; Mazur, M.; Goltzman, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letesse  
Prbc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002  
A:Title: The genome sequence of the facultative intracellular pathogen *Bruceella melitensis*  
A:Reference number: AD3252; PMID:11756688  
A:Accession: AD3607  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-322 <UNR>  
A:Cross-references: UNIPARC:UPI00000585FA; GB:AE008918; PID:gi7984975;  
A:Experimental source: strain 16M  
A:Genetics:

A;Gene: BMEII0781  
A;Map position: II  
C;Superfamily: homoserine O-succinyltransferase  
C;Keywords: acyltransferase; coenzyme A

Query Match 36.5%; Score 647.1; DB 2; Length 322;  
Best Local Similarity 38.8%; Pred. No. 5.6e-20;  
Matches 124; Conservative 61; Mismatches 106; Indels 29; Gaps 3;

QY	1	MPTRVDELPVNFLEENVFVMTTSTRASQEIIRPLKVLILNMPKXIETENOFRLLSN	60
Db	17	MPKIPDDLPAHSVLEAEGVMWREADAVRODIRPLRIGLLNLMPNKVTTETQIARLGA	76
QY	61	SPLQVDIQLLRIDRSRNTPAEHLNFYCNFEDIQDNFDDGLIVTGAPLGLVEFNVDVAY	120
Db	77	TPLQVELTIVRMTNHHVARTPADHMLSFYCPWEEVNDQRFDGVEVITGAPVERLPFEVTV	136
QY	121	WPQIKOVLEWSKHDTSTLFCWAAQAAANILYGIPIKQRTETKLSGVYEHILHPHALLT	180
Db	137	WQEMRNVFMTQSHVHRTLNI CWAAQAAVYHFHGMKKYDLPKAKASGVFORSLVASPYL	196
QY	181	RGFDSDSFAPHGSRV-----ADPFAALIRVDTLEILAEETEGDAYILFASKDKRIAFVYGH	235
Db	197	RGFSDDFALPVSRWTEVRKSDLPAD-----SGLKVLVDSTETGCLGDDDPRHSLHMFNH	251
QY	236	PRYDAQTLAQEPFRDVEAGLDPDVVPYNYFPHNDPQNTPRASWRSHGNLFTNNLNVVYVQ	295
Db	252	VEYDVTTSLADEYFRDIQVQPEAKVPVNYFPGDDAKPPENRWRSHALLFGNWIN-----	306
QY	296	ISYIHHYLLVNNSTELMMHT	315
Db	307	-----EMVQST	312

Search completed: August 1, 2006, 04:30:16  
Job time : 22.8385 secs